Advertencia Respecto al Antibiótico LINEZOLID

La FDA emitió el 16 de marzo de este año un advertencia sobre el uso de Linezolid. Se ha publicado evidencia de aumento de mortalidad en pacientes tratados con este antibiótico en sepsis por cateter causado por bacterias gram negativas solas o combinadas con gram positivas.
Esta información esta disponible en www.fda.org.

A continuación pueden ver la advertencia publicada:

Zyvox (Linezolid)
Audience: Infectious disease specialists, other healthcare professionals[Posted 03/16/2007] FDA notified healthcare professionals of new emerging safety concerns about Zyvox (linezolid) from a recent clinical study. This open-label, randomized trial compared linezolid to vancomycin, oxacillin, or dicloxacillin in the treatment of seriously ill patients with intravascular catheter-related bloodstream infections including those with catheter-site infections. Patients treated with linezolid had a higher chance of death than did patients treated with any comparator antibiotic, and the chance of death was related to the type of organism causing the infection. Patients with Gram positive infections had no difference in mortality according to their antibiotic treatment. In contrast, mortality was higher in patients treated with linezolid who were infected with Gram negative organisms alone, with both Gram positive and Gram negative organisms, or who had no infection when they entered the study.

Linezolid is not approved for the treatment of catheter-related bloodstream infections, catheter-site infections, or for the treatment of infections caused by Gram negative bacteria. If infection with Gram negative bacteria is known or suspected, appropriate therapy should be started immediately